20 October 2022 | News
Etana became the first pharmaceutical company in ASEAN to have mRNA technology.
Photo Credit: Etana Biotechnologies Indonesia
PT Etana Biotechnologies Indonesia (Etana) on 7 October, 2022, inaugurated a biopharmaceutical factory located across 6,471 m2 in the Pulogadung Industrial Estate (JIEP), in East Jakarta. With this Etana became the first pharmaceutical company in ASEAN to have mRNA technology.
Etana is a biopharmaceutical start-up company involved in developing a variety of innovative therapeutics, like vaccines, cancer drugs, and other biological products. This factory has latest technological facilities, quality systems with international standards.
President of the Republic of Indonesia, Ir. H. Joko Widodo, inaugurated the factory along with Coordinating Minister for Maritime Affairs and Investment, Luhut Binsar Pandjaitan; Minister of Health, Budi Gunadi Sadikin; and Head of the Food and Drug Administration (BPOM), Penny K. Lukito; and President Director of Etana, Nathan Tirtana. The factory has been certified with Good Manufacturing Practices (CPOB) from BPOM since December 2019.
Etana will be producing a Covid-19 vaccine with an mRNA platform in collaboration with Chinese companies, Yuxi Walvax Biotechnology Co., Ltd. (Walvax) and Suzhou Abogen Biosciences Co., Ltd. (Abogen), through technology transfer. With this technology, Etana can also produce the first locally produced Covid-19 vaccine in Indonesia called InaRNAVac.
In addition, Etana will produce Erythropoietin (EPO) that is needed in dialysis treatment. Onward, the company plans to develop an adenovirus platform for vaccine production. The production is intended to meet domestic needs and is planned to be exported to the ASEAN market and several other countries.
Etana envisions to expand production facilities for multiplatform drug substance for monoclonal antibodies and adenoviruses.